Company intelligence / Profile preview
Tranzyme Pharma
- Ownership
- Private
- Development stage
- Phase 3
Overview
Tranzyme Pharma developed novel small molecule macrocyclic drugs using its proprietary MATCH™ technology. The company advanced several internal programs targeting GI motility disorders into clinical trials and established major pharma collaborations. In early 2013, it merged with Ocera Therapeutics to form a NASDAQ-listed company focused on liver disease therapeutics.
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Small molecules (specifically macrocyclic compounds)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Tranzyme Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tranzyme Pharma.